The British Paediatric Neurology Association (BPNA) and James Lind Alliance have just launched a Priority Setting Partnership (PSP) survey to help define the Top 10 unanswered questions about the treatment of Childhood Neurological Conditions. For more information about the Priority Setting Partnership please visit the BPNA website which sets out the objectives and who is involved in the Steering Group.
In order to gain insight into the impact of the COVID-19 pandemic on children with disabilities, their families and service providers/professionals across Europe, the European Academy of Childhood Disability (EACD) performed an online survey among 1663 professionals working in the area of childhood-onset disability, and an online survey among 1790 families with one or more individual(s) with a childhood-onset disability in April–May 2020.
Sussex Community NHS Foundation Trust and Newcastle University are contacting professionals working in multi-disciplinary autism diagnostic assessment teams in paediatric or CAMHS/CYPS about diagnostic services and local pathways.
The impact of the COVID-19 pandemic has been widespread, affecting the lives of every baby, child and young person in the country. This generation of children face unprecedented threats to their childhoods. They deserve an unprecedented response.
BACD and The Castang Foundation support UK research that includes children with neurodisability and their families, and are working together to invite research applications to improve the evidence around what treatments and interventions are effective, or not effective for children and families.
The Advisory Committee on Clinical Excellence Awards (ACCEA) has suspended applications for the 2020 national Clinical Excellence Awards competition – there is now no need to complete an application or for employers to sign-off those already submitted.
The UK and Ireland Upper Limb Rehabilitation Network has produced a consensus level guidance document to support the clinical reasoning and processes that accompany the administration of Botulinum Toxin Type A as an adjunct to evidence-based upper limb therapy in children and young people under 19 years of age.
The Castang Foundation is working in partnership with the National Institute for Health Research (NIHR) Academy to co-fund an NIHR-Castang Advanced Fellowship in 2019, which are designed for researchers at a postdoctoral level who: